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Abstract
Background: Placebo treatment can significantly influence subjective symptoms. However, it is widely believed that
response to placebo requires concealment or deception. We tested whether open-label placebo (non-deceptive and non-
concealed administration) is superior to a no-treatment control with matched patient-provider interactions in the treatment
of irritable bowel syndrome (IBS).
Methods: Two-group, randomized, controlled three week trial (August 2009-April 2010) conducted at a single academic
center, involving 80 primarily female (70%) patients, mean age 47618 with IBS diagnosed by Rome III criteria and with a
score $150 on the IBS Symptom Severity Scale (IBS-SSS). Patients were randomized to either open-label placebo pills
presented as ‘‘placebo pills made of an inert substance, like sugar pills, that have been shown in clinical studies to produce
significant improvement in IBS symptoms through mind-body self-healing processes’’ or no-treatment controls with the
same quality of interaction with providers. The primary outcome was IBS Global Improvement Scale (IBS-GIS). Secondary
measures were IBS Symptom Severity Scale (IBS-SSS), IBS Adequate Relief (IBS-AR) and IBS Quality of Life (IBS-QoL).
Findings: Open-label placebo produced significantly higher mean (6SD) global improvement scores (IBS-GIS) at both 11-
day midpoint (5.261.0 vs. 4.061.1, p,.001) and at 21-day endpoint (5.061.5 vs. 3.961.3, p=.002). Significant results were
also observed at both time points for reduced symptom severity (IBS-SSS, p=.008 and p=.03) and adequate relief (IBS-AR,
p=.02 and p=.03); and a trend favoring open-label placebo was observed for quality of life (IBS-QoL) at the 21-day
endpoint (p=.08).
Conclusion: Placebos administered without deception may be an effective treatment for IBS. Further research is warranted
in IBS, and perhaps other conditions, to elucidate whether physicians can benefit patients using placebos consistent with
informed consent.
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Citation: Kaptchuk TJ, Friedlander E, Kelley JM, Sanchez MN, Kokkotou E, et al. (2010) Placebos without Deception: A Randomized Controlled Trial in Irritable
Bowel Syndrome. PLoS ONE 5(12): e15591. doi:10.1371/journal.pone.0015591
Editor: Isabelle Boutron, University Paris Descartes, France
Received August 24, 2010; Accepted November 13, 2010; Published December 22, 2010
This is an open-access article distributed under the terms of the Creative Commons Public Domain declaration which stipulates that, once placed in the public
domain, this work may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose.
Funding: This study was partially supported by grant K24 AT004095, R01 AT00402-01 and R01AT004662 from National Center for Complementary and
Alternative Medicine-NIH and in part from a gift from The Bernard Osher Foundation. The opinions expressed by the authors are their views alone and do not
reflect the official views or policy of the National Center for Complementary and Alternative Medicine, National Institutes of Health, Public Health Service or the
U.S. Department of Health and Human Services. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the
manuscript.
Competing Interests: AJL has worked as a consultant for Ironwood, GSK, Salix, Alkermes, and Ardelyx. These companies have had no relationship to this study.
All other authors report no competing interest or appearance of competing interest.
* E-mail: ted_kaptchuk@hms.harvard.edu
Introduction
Placebo treatment can have a significant impact on subjective
complaints. [1]Furthermore, recent studies haveshown measurable
physiological changes in response to placebo treatment that could
explain how placebos alter symptoms. [2] A critical question is
establishing how physicians and other providers can take optimal
advantage of placebo effects consistent with their responsibility to
fosterpatient trustandobtaininformedconsent.Directlyharnessing
placeboeffectsinaclinicalsettinghasbeen problematicbecauseofa
widespread belief that beneficial responses to placebo treatment
require concealment or deception. [3] This belief creates an ethical
conundrum: to be beneficial in clinical practice placebos require
deceptionbutthis violates the ethical principlesofrespectforpatient
autonomy and informed consent. In the clinical setting, prevalent
ethical norms emphasize that ‘‘the use of a placebo without the
patient’s knowledge may undermine trust, compromise the patient-
physician relationship, and result in medical harm to the patient.’’
[4] Nevertheless, a recent national survey of internists and
rheumatologists in the US found that while only small numbers of
PLoS ONE | www.plosone.org 1 December 2010 | Volume 5 | Issue 12 | e15591US physicians surreptitiously use inert placebo pills and injections,
approximately 50% prescribe medications that they consider to
have no specific effect on patients’ conditions and are used solely as
placebos (sometimes called ‘‘impure placebos.’’) [5] Many other
studiesconfirmthisfinding.[6]Giventhis situation,findingeffective
means of harnessing placebo responses in clinical practice without
deception is a high priority.
Irritable bowel syndrome (IBS) is one of the top 10 reasons for
seeking primary care and with a world-wide prevalence of
approximately 10 to 15%. [7,8] It is a chronic functional
gastrointestinal disorder characterized by abdominal pain and
discomfort associated with altered bowel habits. [9] The symptoms
of IBS not only adversely affect a person’s health-related quality of
life (QOL), [10,11] but are associated with a substantial financial
burden of reduced work productivity and an over 50% increase in
the use of health-related resources. [11,12] While many therapies
are commonly used to treat individual IBS symptoms such as
constipation or diarrhea, few therapies have been shown to be
effective and safe in relieving the global symptoms of IBS. [11,13]
Previous research has demonstrated that placebo responses in IBS
are substantial and clinically significant. [14,15] Furthermore, data
from our previous qualitative study of IBS patients being treated
single-blind with placebos indicated that patients can tolerate a
high degree of ambiguity and uncertainty about placebo treatment
and still benefit. [16] In view of these considerations, we selected
IBS as a suitable condition to test the widespread belief that
placebo responses are neutralized by awareness or knowledge that
the treatment is a placebo.
The objectives of this study were to assess the feasibility of
recruiting IBS patients to participate in a trial of open-label
placebo and to assess whether an open-label placebo pill with a
persuasive rationale was more effective than no-treatment in
relieving symptoms of IBS in the setting of matched patient-
provider interactions.
Methods
Design
A three week randomized controlled trial (RCT) comparing
open-label placebo to no-treatment controls was conducted
between August 2009 and April 2010 in a single academic
medical center. Written informed consent was obtained from each
patient prior to participation on the study. The Beth Israel
Deaconess Medical Center Institutional Review Board approved
the design and informed consent.
Patients who gave informed consent and fulfilled the inclusion
and exclusion criteria were randomized into two groups: 1)
placebo pill twice daily or 2) no-treatment. Before randomization
and during the screening, the placebo pills were truthfully
described as inert or inactive pills, like sugar pills, without any
medication in it. Additionally, patients were told that ‘‘placebo
pills, something like sugar pills, have been shown in rigorous
clinical testing to produce significant mind-body self-healing
processes.’’ The patient-provider relationship and contact time
was similar in both groups. Study visits occurred at baseline (Day
1), midpoint (Day 11) and completion (Day 21). Assessment
questionnaires were completed by patients with the assistance of a
blinded assessor at study visits. (The protocol for this trial and
supporting CONSORT checklist are available as supporting
information; see Checklist S1 and Protocol S1.)
Patients
Participants were recruited from advertisements for ‘‘a novel
mind-body management study of IBS’’ in newspapers and fliers
and from referrals from healthcare professionals. During the
telephone screening, potential enrollees were told that participants
would receive ‘‘either placebo (inert) pills, which were like sugar
pills which had been shown to have self-healing properties’’ or no-
treatment. Participants were adults ($18 years old) meeting the
Rome III criteria for IBS [17] with a score of $150 on the IBS
Symptom Severity Scale (IBS-SSS). [18] The diagnosis of IBS was
based on typical symptoms and exclusion of patients with alarm
symptoms. [19,20] was confirmed by a board certified gastroen-
terologist (AJL) or a nurse practitioner (EF) experienced in
functional bowel disorders. Patients were excluded if they had
any unexplained alarm features (i.e. weight loss .10% body
weight, fevers, or blood in stools, or had family history of colon
cancer, or inflammatory bowel disease). Patients with a history of
pelvic floor dyssynergia, the need to use manual maneuvers in
order to achieve a bowel movement, surgery of the colon at any
time, abdominal surgery within 60 days prior to entry into the
study, or laxative abuse were excluded from the study. Patients
with other medical conditions (e.g., neurological disorders,
metabolic disorders, or other significant disease), or pretreatment
laboratory or ECG findings believed to impair their ability to
participate in the study were also excluded. Any surgery within the
past 30 days, pregnancy, breast-feeding, or participation in
another clinical study within 30 days prior to the start of the
study were also disqualifying factors.
Patients were allowed to continue IBS medications (e.g., fiber,
anti-spasmodics, loperamide, etc.) as long as they had been on
stable doses for at least 30 days prior to entering the study and
agreed not to change medications or dosages during the trial.
Patients were asked to refrain from making any major life-style
changes (e.g., starting a new diet or changing their exercise
pattern) during the study.
Interventions
Patients were randomly assigned either to open-label placebo
treatment or to the no-treatment control. Prior to randomization,
patients from both groups met either a physician (AJL) or nurse-
practitioner (EF) and were asked whether they had heard of the
‘‘placebo effect.’’ Assignment was determined by practitioner
availability. The provider clearly explained that the placebo pill
was an inactive (i.e., ‘‘inert’’) substance like a sugar pill that
contained no medication and then explained in an approximately
fifteen minute a priori script the following ‘‘four discussion points:’’
1) the placebo effect is powerful, 2) the body can automatically
respond to taking placebo pills like Pavlov’s dogs who salivated
when they heard a bell, 3) a positive attitude helps but is not
necessary, and 4) taking the pills faithfully is critical. Patients were
told that half would be assigned to an open-label placebo group
and the other half to a no-treatment control group. Our rationale
had a positive framing with the aim of optimizing placebo
response. It was emphasized that each group was critical for the
trial. All patients were told that they would receive educational
recommendations for their IBS at the end of the study. After
completion of the physical examination and assessments, patients
were then randomized using a sequentially numbered opaque
sealed envelopes that contained treatment assignments drawn
from a computer-generated random number sequence. Until this
point, the patient-provider interaction --- including delivering the
persuasive rationale and the explanation of the importance of both
groups – was similar for all participants. At this point, during the
last moments of the interview, they were told their assignments.
Patients randomized to the open-label placebo group were given a
typical prescription medicine bottle of placebo pills with a label
clearly marked ‘‘placebo pills’’ ‘‘take 2 pills twice daily.’’ The
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avicel, a common inert excipient for pharmaceuticals (Bird’s Hill
Pharmacy, Needham, MA). Patients in the no treatment arm were
reminded of the importance of the control arm. All visits were in
the context of a warm supportive patient-practitioner relationship.
The midpoint 11 day visit was brief (approximately 15 minutes)
and included an opened question regarding adverse events,
concomitant medications and a brief physical examination. After
the examination, a treatment-blind researcher administered
questionnaires. Patients receiving placebos received a short
reminder regarding the ‘‘four discussion points.’’ In the no
treatment arm, patients were encouraged and thanked for helping
make a successful study.
Before the study began the providers practiced the trial
procedures on simulated and real patients. Once a month, the
two providers (AJL, EF) and a third researcher (TJK) met to
discuss fidelity to the protocol and any other problems. AJL and
EF consistently reported that they had no problem holding the
entire initial interview process to approximately 30 minutes and
the mid-point to 15 minutes.
Assessment
Our primary outcome measure was the IBS Global Improve-
ment Scale (IBS-GIS) which asks participants: ‘‘Compared to the
way you felt before you entered the study, have your IBS
symptoms over the past 7 days been: 1) Substantially Worse, 2)
Moderately Worse, 3) Slightly Worse, 4) No Change, 5) Slightly
Improved, 6) Moderately Improved or 7) Substantially Im-
proved.[21,22] Other measures included: the IBS-SSS measure,
which contains five 100-point scales, that assess the severity of
abdominal pain, the frequency of abdominal pain, the severity of
abdominal distention, dissatisfaction with bowel habits, and
interference with quality of life, [18] All 5 components contribute
to the score equally yielding a theoretical range of 0–500, with a
higher score indicating greater symptom severity. The IBS-
Adequate Relief (IBS-AR) is a single dichotomous (yes or no)
item that asks participants ‘‘Over the past week have you had
adequate relief of your IBS symptoms?’’ [23] The IBS-QoL is a
34-item measure assessing the degree to which IBS interferes with
patient quality of life. Each item is rated on a 5-point Likert scale
and a linear transformation yields a summed score with a
theoretical range of 0 to 100, with a higher score indicating better
quality of life. [24] Side effects were recorded at each assessment.
A pill count was taken at visits two and three. Given the
unprecedented nature of the study, at the completion of the trial
patients were given a short qualitative open-ended check-out
questionnaire and asked for written responses. The questions were
different for each group. Those in the placebo treatment arm were
asked four questions: What do you think of about the idea of
taking placebo? Did you expect it to work or were you skeptical?
What did you think was in the placebo pills? Any further
comments? Those in the no-treatment were asked three questions:
Were you disappointed to be in the treatment as usual arm? What
did you like most and least about the trial? Any further comments?
All assessments were performed by a researcher who was blind to
treatment assignment.
Statistical Analysis
All tests were two-tailed with alpha set at .05. All results are
reported as mean 6SD unless otherwise noted. All analyses were
intent-to-treat, and missing data were replaced using the last
observation carried forward method. Since IBS-GIS and IBS-AR
are change scores and are not assessed at baseline, we carried
forward scores for patients who had at least one follow-up visit. For
our main outcome measure (IBS-GIS at 21-day endpoint), we
planned an independent samples t-test. We estimated a priori that a
total sample size of 80 would provide 94% power to detect a large
effect (d=.8) and 60% power to detect a medium effect (d=.5). For
IBS-SSS and IBS-QOL, we computed change scores from baseline
and then conducted independent samples t-tests. We used chi
square tests of independence for IBS-AR. Per protocol analyses
were also conducted, but they produced no substantive differences
from our planned intent-to-treat analyses and are not reported here.
Results
As shown in Figure 1, 92 patients were screened, and 80 eligible
patients were randomized into the two arms (43 into no-treatment
and 37 into open-label placebo). There were missing outcome data
for 13 patients at midpoint (16%; 6 no-treatment control, 7 open-
label placebo), and for 10 patients at endpoint (13%; 4 no-
treatment control, 6 open-label placebo). As noted above, missing
data was replaced using the last observation carried forward
method. Table 1 shows baseline data.
As shown in Figure 2 and Table 2, patients treated with open-
label placebo had significantly greater scores than the no-
treatment control on the main outcome measure, Global
Improvement Scale (IBS-GIS), at both the 11-day midpoint
(5.261.0 vs. 4.061.1, p,.001, d=1.14) and the 21-day endpoint
(5.061.5 vs. 3.961.3, p=.002, d=0.79). In addition, there were
statistically significant differences at both time points on reduction
on in symptom severity (IBS-SSS) and adequate relief (IBS-AR),
and a trend toward significance at the 21-day endpoint on
improvement in quality of life (IBS-QOL).
Forty-three patients saw the male physician for all three visits,
20 patients saw the female nurse-practitioner for all three visits,
and 17 patients saw a combination of the two or missed a
treatment session. Given that the two treatment providers differed
by gender and discipline (MD vs. NP), we tested for differences in
treatment outcomes. No significant differences were found
between providers on the primary outcome measure, IBS-GIS
(p=.57 at midpoint, and p=.51 at endpoint). Similarly, there
were no significant differences between providers on any of the
secondary outcome measures.
Adverse events were reported by only three placebo-treated
patients (8%) at midpoint and five patients (14%) at endpoint. The
most common adverse events that patients reported were upper
respiratory infection (N=3) and pain (N=2); other events
included rash, runny stools, and a sty on the eye.
The detailed results of the qualitative check-out questionnaire
will be reported elsewhere. However, responses to two questions
seemed especially relevant to the interpretation of this quantitative
report. Specifically, 1) did patients in the open-label arm
understand that they were taking a placebo (‘‘What did you think
was in the placebo pills?’’) and 2) were patients in the no treatment
arm disappointed (‘‘Were you disappointed to be in the treatment
as usual arm?’’) To answer these questions two researchers (TJK,
MK) independently extracted the responses to these questions. A
third researcher (JPS) compared these extracted responses and a
discussion settled two occasions where handwriting that was
difficult to interpret. TJK categorized the data using the iterative
and emergent methodology of grounded theory. [25,26] When
participants in the placebo arm were asked: ‘‘ What did you think
was in the placebo pills?’’ of the 29 who responded, 16 wrote
‘‘sugar’’ (12), ‘‘flour’’ (3) or ‘‘calcium’’ (1),’’ 6 responded ‘‘nothing,’’
5 responded ‘‘did not know,’’ 1 responded ‘‘symbolic reminder,’’
and 1 responded ‘‘possible test medication.’’ When participants in
the no-treatment arm were asked: ‘‘Were you disappointed to be
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‘‘no’’ and only 9 said ‘‘yes’’ or ‘‘a little’’. We then looked at the
responses of the nine who expressed disappointment, to see how
they responded to: ‘‘What did you like most and least about the
trial?’’ All gave uniformly positive answers such as ‘‘I liked that my
feeling about the intensity of the problem was validated and was
taken seriously…and was able to discuss my IBS,’’ ‘‘the doctor and
the nurse were wonderful and accommodating,’’ ‘‘I liked the one-
on-one attention with the MD, able to ask questions about IBS
with a person trained in the illness; this MD is very kind’’
(underling in the original). This qualitative data seemed to indicate
that, in general, patients understood they were taking placebo and
were not overly disappointed in being in the no-treatment arm.
Discussion
We found that patients given open-label placebo in the context
of a supportive patient-practitioner relationship and a persuasive
Figure 1. Enrollment Flowchart.
doi:10.1371/journal.pone.0015591.g001
Table 1. Demographics and Baseline Characteristics.
Demographics and Baseline Characteristics
No Treatment
(N=43)
Open Placebo
(N=37)
Age 46618 47618
Female – no. (%) 32 (74) 24 (65)
White – no. (%) 36 (84) 26 (70)
IBS Type – no. (%)
Diarrhea Predominant 16 (37) 10 (27)
Constipation Predominant 14 (33) 16 (43)
Mixed 13 (30) 11 (30)
IBS Duration in Years 13611 16612
Symptom Severity (IBS-SSS) 297658 310682
Quality of Life (IBS-QOL) 59621 55621
Upper GI Symptoms (GERD & Dyspepsia) – no. (%) 18 (42) 11 (30)
Taking Medications for IBS – no. (%) 15 (35) 20 (54)
Taking Antidepressants – no. (%) 7 (16) 9 (24)
Note: All values are means 6SD, unless otherwise noted. Group differences were examined using independent t-tests for continuous measures and chi square test for
categorical measures.. IBS = irritable bowel syndrome; IBS-SSS = IBS Symptom Severity Scale; IBS-QOL = IBS Quality of Life Scale; GI = Gastrointestinal; GERD =
Gastroesophageal Reflux Disease.
doi:10.1371/journal.pone.0015591.t001
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was significantly better than a no-treatment control group with
matched patient-provider interaction. To our knowledge, this is
the first RCT comparing open-label placebo to a no-treatment
control. Previous studies of the effects of open-label placebo
treatment either failed to include no-treatment controls [27] or
combined it with active drug treatment. [28] Our study suggests
that openly described inert interventions when delivered with a
plausible rationale can produce placebo responses reflecting
symptomatic improvements without deception or concealment.
Figure 2. Outcomes at the 21-Day Endpoint by Treatment Group.
doi:10.1371/journal.pone.0015591.g002
Table 2. Treatment Outcomes.
No Treatment
(N=43)
Open Placebo
(N=37) p-value
Midpoint (11 Days)
Global Improvement (IBS-GIS) 4.061.1 5.261.0 ,.001
Adequate Relief (IBS-AR) – no. (%) 10 (23) 18 (49) .02
Symptom Severity Reduction (IBS-SSS) 28666 75687 .008
Quality of Life Improvement (IBS-QoL) 4.468.9 8.3611.6 .10
Endpoint (3 Weeks)
Global Improvement (IBS-GIS) 3.961.3 5.061.5 .002
Adequate Relief (IBS-AR) – no. (%) 15 (35) 22 (59) .03
Symptom Severity Reduction (IBS-SSS) 46674 92699 .03
Quality of Life Improvement (IBS-QoL) 5.4613.8 11.4616.6 .08
Note: All values are means 6SD except where noted. IBS = irritable bowel syndrome; IBS-GIS = IBS Global Improvement Scale; IBS-AR = IBS Adequate Relief;
IBS-SSS = IBS Symptom Severity Scale; IBS-QoL = IBS Quality of Life Scale.
doi:10.1371/journal.pone.0015591.t002
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effects require ‘‘intentional ignorance.’’ [29] Our data suggest that
harnessing placebo effects without deception is possible in the
context of 1) an accurate description of what is known about
placebo effects, 2) encouragement to suspend disbelief, 3)
instructions that foster a positive but realistic expectancy, and 4)
directions to adhere to the medical ritual of pill taking. It is likely
our study also benefited from ongoing media attention giving
credence to powerful placebo effects.
Both treatment arms were given in a context of a warm patient-
provider relationship. It is possible that this relationship had a
positive benefit for the patients, and indeed, the no-treatment arm
showed improvement. Given that patients in both treatment arms
experienced the same frequency and duration of contact time and
the content of the interaction was very similar, we believe that the
incremental improvement in our open-label arm was due to the
addition of open-label placebo treatment. The magnitude of
improvement reported by those on open-label placebo treatment
was not only statistically significant but also clinically meaningful.
The effect size for the primary outcome, calculated as the
standardized mean difference (d) between the open-label-placebo
and no-treatment groups, was 0.79 at endpoint, which is
conventionally interpreted as a large effect. [30] At endpoint, we
also observed medium sized effects for the differences between
placebo and control groups on symptom severity (d=0.53) and
quality of life (d=0.40). An improvement from baseline of 50
points on the IBS-SSS reliably indicates meaningful symptomatic
improvement. [18] The open-label group improved by 92 points
on this measure; in addition, the improvement shown by the open-
label placebo group exceeded that shown by the no-treatment
group by 46 points. Similarly, an increase of 10 points on the IBS-
QoL indicates a clinically meaningful improvement, and we
observed an increase of 11 points on this measure for the open-
label group. [24] Finally, the percentage of patients reporting
adequate relief during the preceding 7 days at the 21-day endpoint
(59%) is comparable with the responder rates in clinical trials of
drugs currently used in IBS. [31,32] A recent meta-analysis of
double-blind, placebo-controlled trials of alosetron in IBS
estimated that 51% of patients treated with alosetron had
adequate relief as compared to 38% of patients treated with
placebo. [33] Our results were remarkably similar (59% for open-
placebo; 35% for no-treatment control), suggesting that open-label
placebo in the context of a persuasive rationale may show
comparable efficacy to established IBS treatments.
The placebo response in this trial (59% on IBS-AR) was
substantially higher than typical reported placebo responses of 30–
40% in double-blind IBS pharmaceutical studies. [15] This finding
seems counterintuitive. We speculate that it is an indication of the
credibility of our open-label rationale. Patients in our study
accepted that they were receiving an active treatment, albeit not a
pharmacological one, whereas patients in double-blind trials
understand that they have only a 50% chance of receiving active
treatment. It may be that one hundred percent certainty that one
is receiving the ‘‘treatment of interest’’ (in this case open-label
placebo) is more placebogenic than a fifty percent probability of
receiving an inactive control.
It may be worthwhile to interpreted our study in light of the
2001 landmark meta-analysis of placebo effects and its 2010
expanded and updated version. [34,35] In the recent analysis, the
authors found 202 randomized trials in 60 medical conditions that
included placebo and no-treatment groups. When meta-analyti-
cally combined, in general, little evidence of clinically meaningful
effects of placebo beyond no treatment was found. The meta-
analysis, however demonstrated a significantly larger placebo
effect for a subset of 28 studies with a specific aim of investigating
the placebo effect. Perhaps this subset is most relevant to our study
which was also specifically examined placebo effects. Further
prospective research will be necessary to clarify under what
circumstances and in what conditions one can expect or not expect
to find robust placebo responses.
There are intimations in the placebo literature that providers
with greater perceived expertise or authority (e.g., physician versus
nurse, dentist versus technician) will elicit greater placebo
responses. [36,37] In our study, we found no evidence for
significant differences between male physician and female nurse-
practitioner.
In addition to its clinical significance, our study has important
ethical implications. As mentioned above, evidence indicates that
physicians continue to use placebo treatment without transparent
disclosure to patients [5,6] Our results suggest that the placebo
response is not necessarily neutralized when placebos are
administered openly. Thus our study points to a potential novel
strategy that might allow the ethical use of placebos consistent with
evidence-based medicine. Minimally, open-label placebo may
have potential as a ‘‘wait and watch’’ strategy before prescriptions
drugs are prescribed. Further studies of open placebo are merited
not only for IBS but for illnesses primarily diagnosed by subjective
symptoms and introspective self-appraisal. In sum, our study
suggests that for some disorders it may be appropriate for
clinicians to recommend that patients try an inexpensive and safe
placebo accompanied by careful monitoring before and after
prescribing medication. Clearly replication and further research is
essential before such a practice could be implemented.
Limitations
This RCT has several limitations. Most importantly, our sample
size was relatively small and the trial duration was too short to
obtain estimates of long-term effects. Therefore, the trial could be
described as a ‘‘proof-of-principle’’ pilot study. Obviously,
replication with a larger sample size and a longer follow-up is
needed before clear clinical decisions could be made based on our
data.
Other potential limitations of our study may be the issue of
report bias (e.g., ‘‘wishing to please the experimenter’’). However,
given the impossibility of double-blind assessment of open placebo
versus no-treatment control, the effects of report bias cannot be
eliminated. Another related limitation is that patients assigned to
no-treatment may have been disappointed, thus inflating the
differences between open-label placebo and no-treatment control
groups. Importantly, our qualitative check-out data found the no-
treatment group experiencing positive support, with 76% of them
reporting that they were not disappointed with their assignment.
This argues against disappointment being a significant factor. A
further possible limitation is that our results are not generalizable
because our trial may have selectively attracted IBS patients who
were attracted by an advertisement for ‘‘a novel mind-body’’
intervention. Obviously, we cannot rule out this possibility.
However, selective attraction to the advertised treatment is a
possibility in virtually all clinical trials. In any case, patients in
clinical practice are ultimately given choices and it may turn out
that open-label placebo will be helpful only for those who elect to
try this option. Finally, it could be argued that IBS is a poor illness
to study placebo effects because it lacks objective measures.
However, there are many serious conditions for which primary
outcomes are primarily subjective (e.g. depression, anxiety and
chronic pain), and the preponderance of evidence indicates that
placebo treatments are most effective for such patient-centered
complaints. [1]
Placebos without Deception
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open-label placebos and that such a treatment may have
salubrious effects. Further research is warranted in IBS and
perhaps other illnesses to confirm that placebo treatments can be
beneficial when provided openly and to determine the best
methods for administering such treatments.
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